RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Date
2024-06-04ICR Author
Author
Carmichael, J
Figueiredo, I
Gurel, B
Beije, N
Yuan, W
Rekowski, J
Seed, G
Carreira, S
Bertan, C
Fenor de la Maza, MDLD
Chandran, K
Neeb, A
Welti, J
Gallagher, L
Bogdan, D
Crespo, M
Riisnaes, R
Ferreira, A
Miranda, S
Lu, J
Shen, MM
Hall, E
Porta, N
Westaby, D
Guo, C
Grochot, R
Lord, CJ
Mateo, J
Sharp, A
de Bono, J
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial. METHODS: Whole tumor biopsies from multiple cohorts of patients with advanced prostate cancer were interrogated using whole-exome sequencing (WES), RNA sequencing (bulk and single nucleus) and immunohistochemistry (IHC) for RNASEH2B and RB1. Biopsies from patients treated with olaparib in the TOPARP-A and TOPARP-B clinical trials were used to evaluate RNASEH2B clonal selection during olaparib treatment. RESULTS: Shallow co-deletion of RNASEH2B and adjacent RB1, co-located at chromosome 13q14, was common, deep co-deletion infrequent, and gene loss associated with lower mRNA expression. In castration-resistant PC (CRPC) biopsies, RNASEH2B and RB1 mRNA expression correlated, but single nucleus RNA sequencing indicated discordant loss of expression. IHC studies showed that loss of the two proteins often occurred independently, arguably due to stochastic second allele loss. Pre- and post-treatment metastatic CRPC (mCRPC) biopsy studies from BRCA1/2 wildtype tumors, treated on the TOPARP phase II trial, indicated that olaparib eradicates RNASEH2B-loss tumor subclones. CONCLUSION: PARP inhibition may benefit men suffering from mCRPC by eradicating tumor subclones with RNASEH2B loss. CLINICALTRIALS: gov NCT01682772FUNDING. AstraZeneca; Cancer Research UK; Medical Research Council; Cancer Research UK; Prostate Cancer UK; Movember Foundation; Prostate Cancer Foundation.
Collections
Subject
Oncology
Prostate cancer
Research team
Cancer Biomarkers
Clin Trials & Stats Unit
Translational Therapeutic
Gene Function
PrCa Targeted Therapy
Language
eng
Date accepted
2024-06-04
License start date
2024-06-04
Citation
Journal of Clinical Investigation, 2024, pp. e178278 -
Publisher
American Society for Clinical Investigation